India cuts prices of 543 cancer-drug brands under 30% trade-margin cap

India's National Pharmaceutical Pricing Authority (NPPA) on 28 October published revised maximum retail prices for 543 brands of anti-cancer medicines, putting into effect the 30% cap on trade margins it announced on 17 October. Retailers and hospitals must charge the reduced prices from 9 November. The regulator said the cap, which covers 137 non-scheduled formulations, would cut retail prices by up to 70% depending on existing price structures, and the government estimates that the broader initiative could save cancer patients about Rs 2,500 crore a year.

The measure uses the Trade Margin Rationalisation mechanism under Paragraph 19 of the Drugs (Prices Control) Order 2013, which allows the government to act on prices in the public interest, and was introduced through a gazette notification. Non-scheduled medicines sit outside India's ceiling-price regime, so manufacturers ordinarily set their own retail prices. Rather than fixing a price, the margin cap limits how much can be added between the manufacturer and the patient. The list of 137 drugs came from an expert committee under the Directorate General of Health Services, made up of oncologists, other specialists, hospital experts and officials, and will be updated periodically.

The published examples show how wide some margins had become. RPG Life Sciences' Anarzole, a pack of ten 1 mg anastrozole tablets, falls from Rs 695.76 to Rs 73, a cut of about 90%. Abbott Healthcare's Bevacizab, a 100 mg bevacizumab vial, falls from Rs 21,767.70 to Rs 5,930.13, and RPG's denosumab brand Debrumab from Rs 22,031.25 to Rs 5,941. Hetero Healthcare's fludarabine injection Fludanox drops from Rs 14,235 to Rs 2,432. Other reductions are smaller: Natco Pharma's Dasanat 20, a 60-tablet pack of dasatinib, falls by about 61%, and Neon Laboratories' erlotinib brand Erlib by about 57%.

Several caveats apply. The list reflects price information companies had submitted up to 27 October, so it is unlikely to be complete. The new figures are ceilings, and compliance depends on enforcement by state drug controllers, on manufacturers publishing revised price lists and on hospitals, which must display the new rates and bear direct responsibility for implementation. Patients can check prices on the NPPA website and its Pharma Sahi Daam app. Whether hospital pharmacies, where many cancer treatments are dispensed, pass on the reductions as consistently as retail chemists will be an early test of enforcement.

There is a clear precedent. A pilot in 2019 capped trade margins on 42 anti-cancer drugs at 30% and reduced the retail prices of 526 brands by up to 90%. The new exercise is roughly three times as broad in molecules and extends to costly biologics and supportive-care products, including immunotherapies, bevacizumab, denosumab and pegfilgrastim, where per-dose prices in the thousands of rupees make the margin on each pack material to patients paying out of pocket.

For manufacturers, the financial effect depends on where existing prices sat. Where the cap mainly removes margin previously captured by distributors, retailers and hospitals, ex-factory realisations may change little. Where retail prices were set well above competing brands, companies may have to absorb part of the reduction. The order also requires companies to maintain production and supply of the notified formulations, a safeguard against the risk, which generic manufacturers have warned about elsewhere, that aggressive price pressure undermines dependable supply.

The policy question is whether margin rationalisation becomes a standing tool rather than an occasional intervention. A parliamentary committee on health held meetings on cancer drug prices last month, and the expert committee's list is designed to be revised. If the government extends the approach to other therapeutic areas, the distribution economics of India's branded generics market, rather than manufacturers' list prices alone, will become the main lever of price control. The immediate test is whether the lower prices are visible at hospital counters after 9 November.